News release

Tokyo -- Terumo Corporation (TSE: 4543 Section 1) today announced that the company determined a site for construction near Ho Chi Minh City, Vietnam for a new factory. The new factory will manufacture the products of blood management business that is one of core corporate strategy.
Factory Overview
Corporate name: |
TERUMO BCT VIETNAM CO., LTD. (To be established in December of FY2012) |
Location: |
Long Duc Industrial Park, Dong Nai Province, Vietnam (Suburb of Ho Chi Minh City) |
Land area: | Approximately 100,000 m2 |
Investment amount: | 98.9 million USD |
Projected operation commencement: | Summer in 2015 (plan) |
Production items: | Blood bag, Automated blood collection system disposable kit |
In April 2012, Terumo BCT was established through the integration of CaridianBCT and Terumo Transfusion, following Terumo Corporation's acquisition of CaridianBCT in April 2011.
The global demand for blood transfusion will increase due to the growing surgical cases in emerging countries and the increasing platelet transfusion for cancer patients who suffer platelet loss caused by chemotherapy.
To meet these increasing global demands, Terumo BCT will expand the production capacity by the new factory.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.